A practical reference on tripeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-13 and is reviewed periodically as new material appears.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II)-tripeptide complex | One peptide ligand with one coordinated metal centre |
| Peptide sequence | Gly-His-Lys | Three residues written in one-letter notation |
| Free peptide mass | 340.4 g/mol | Metal-free GHK; the complex has a higher mass |
| Appearance | Blue to violet solid or solution | Colour originates from copper d orbital transitions |
| Storage | Desiccated, -20 °C, protected from light | Dry powder is more stable than dissolved material |
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Stability depends on temperature, light exposure, moisture, and the presence of oxidizing or reducing agents. Solid material held dry and protected from light is generally more stable than aqueous solutions, which can undergo gradual degradation. Recommended storage in much of the literature is a freezer at around minus twenty degrees Celsius for long-term retention, with working aliquots kept cold and shielded from light. Repeated freeze-thaw cycles and alkaline pH are commonly noted as factors that accelerate loss of the intact complex, though exact degradation rates vary.
== Potential applications == A wide variety of potential applications have been envisaged. Since magnetic nanoparticles are expensive to produce, there is interest in their recycling or for highly specialized applications. The potential and versatility of magnetic chemistry arises from the fast and easy separation of the magnetic nanoparticles, eliminating tedious and costly separation processes usually applied in chemistry. Furthermore, the magnetic nanoparticles can be guided via a magnetic field to the desired location which could, for example, enable pinpoint precision in fighting cancer.
In habitual users, however, tolerance develops rapidly; the perceived attention and alertness boost after overnight abstinence primarily reverses mild withdrawal deficits (fatigue, reduced concentration) rather than elevating performance above a true non-dependent baseline, consistent with the withdrawal-reversal hypothesis.
Sydenham's Laudanum: "According to the Paris Codex this is prepared as follows: opium, 2 ounces; saffron, 1 ounce; bruised cinnamon and bruised cloves, each 1 drachm; sherry wine, 1 pint. Mix and macerate for 15 days and filter. Twenty drops are equal to one grain of opium." Rousseau's Laudanum: "Dissolve 12 ounces white honey in 3 pounds warm water, and set it aside in a warm place. When fermentation begins add to it a solution of 4 ounces selected opium in 12 ounces water. Let the mixture stand for a month at a temperature of 86° Fahr.; then strain, filter, and evaporate to 10 ounces; finally strain and add 41⁄2 ounces proof alcohol. Seven drops of this preparation contain about 1 grain of opium." Tincture of Opium (Laudanum), U.S.P., attributed to the United States Pharmacoepia of 1863: "Macerate 21⁄2 ounces opium, in moderately fine powder in 1 pint water for 3 days, with frequent agitation. Add 1 pint alcohol, and macerate for 3 days longer. Percolate, and displace 2 pints tincture by adding dilute alcohol in the percolator."
Sources: en.wikipedia.org
=== Vaginal, rectal, and uterine === Vaginal progesterone suppositories were first studied in women by Robert Greenblatt in 1954. Shortly thereafter, vaginal progesterone suppositories were introduced for medical use under the brand name Colprosterone in 1955. Rectal progesterone suppositories were first studied in men and women by Christian Hamburger in 1965. Vaginal and rectal progesterone suppositories were introduced for use under the brand name Cyclogest by 1976. Vaginal micronized progesterone gels and capsules were introduced for medical use under brand names such as Utrogestan and Crinone in the early 1990s. Progesterone was approved in the United States as a vaginal gel in 1997 and as a vaginal insert in 2007. A progesterone contraceptive vaginal ring known as Progering was first studied in women in 1985 and continued to be researched through the 1990s. It was approved for use as a contraceptive in lactating mothers in Latin America by 2004. A second progesterone vaginal ring known as Fertiring was developed as a progesterone supplement for use during assisted reproduction and was approved in Latin America by 2007. Development of a progesterone-containing intrauterine device (IUD) for contraception began in the 1960s. Incorporation of progesterone into IUDs was initially studied to help reduce the risk of IUD expulsion. However, while addition of progesterone to IUDs showed no benefit on expulsion rates, it was unexpectedly found to induce endometrial atrophy.
In January 1943, Colonel David Stirling was captured in Tunisia and Paddy Mayne replaced him as commander. In April 1943, the 1st SAS was reorganised into the Special Raiding Squadron under Mayne's command and the Special Boat Section was placed under the command of George Jellicoe. The Special Raiding Squadron fought in Sicily and Italy along with the 2nd SAS, which had been formed in North Africa in 1943 in part by the renaming of the Small Scale Raiding Force under the command of Bill Stirling (brother of David). The Special Boat Squadron fought in the Aegean Islands and Dodecanese until the end of the war. In 1944 the SAS Brigade was formed. The unit was formed from:
NAPQI, also known as NAPBQI or N-acetyl-p-benzoquinone imine, is a toxic byproduct produced during the xenobiotic metabolism of the analgesic paracetamol (acetaminophen). It is normally produced only in small amounts, and then almost immediately detoxified in the liver. However, under some conditions in which NAPQI is not effectively detoxified, usually in the case of paracetamol overdose, it causes severe damage to the liver. This becomes apparent 3–4 days after ingestion and may result in death from fulminant liver failure several days after the overdose.
Sources: en.wikipedia.org
=== Availability === Chlorprothixene is widely available throughout Europe and elsewhere in the world. The drug was previously available in the United States under the brand name Taractan, but this formulation has since been discontinued and the drug is no longer available in this country.
6 April U.S. Space Command, based on information collected from its planetary defense sensors, confirms the detection of the first known interstellar object. The purported interstellar meteorite, technically known as CNEOS 2014-01-08, impacted Earth in 2014, and was determined, based on its hyperbolic trajectory and estimated initial high velocity, to be from beyond the Solar System. The 2014 meteorite was detected three years earlier than the more recent and widely known interstellar objects, ʻOumuamua in 2017 and 2I/Borisov in 2019. Further related studies were reported on 1 September 2023. The first known dinosaur fossil linked to the very day of the Chicxulub impact is reported by paleontologists at the Tanis site in North Dakota. One science journalist reflects on the global management of the COVID-19 pandemic in relation to science, investigating the question "Why the WHO took two years to say COVID is airborne" – a finding hundreds of scientists reaffirmed in an open letter in July 2020 – with one indication being that this may be a major concern for many expert scientists, as evidenced by several writings published by news outlets. A study decodes electrical communication between fungi into word-like components via spiking characteristics. Researchers demonstrate semi-automated testing for reproducibility (which is lacking especially in cancer research) via extraction of statements about experimental results in, as of 2022 non-semantic, gene expression cancer research papers and subsequent testing with breast cancer cell lines via robot scientist "Eve".
=== Cancer === LRP1 is involved in tumorigenesis, and is proposed to be a tumor suppressor. Notably, LRP1 functions in clearing proteases such as plasmin, urokinase-type plasminogen activator, and metalloproteinases, which contributes to prevention of cancer invasion, while its absence is linked to increased cancer invasion. However, the exact mechanisms require further study, as other studies have shown that LRP1 may also promote cancer invasion. One possible mechanism for the inhibitory function of LRP1 in cancer involves the LRP1-dependent endocytosis of 2′-hydroxycinnamaldehyde (HCA), resulting in decreased pepsin levels and, consequently, tumor progression. Alternatively, LRP1 may regulate focal adhesion disassembly of cancer cells through the ERK and JNK pathways to aid invasion. Moreover, LRP1 interacts with PAI-1 to recruit mast cells (MCs) and induce their degranulation, resulting in the release of MC mediators, activation of an inflammatory response, and development of glioma.
Sources: en.wikipedia.org
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.
The three letters are the standard one-letter codes for glycine, histidine, and lysine. The suffix -Cu indicates the coordinated copper ion. Cosmetic ingredient lists often use the alternative name copper tripeptide-1 for the same complex.
No. Free GHK is the peptide alone, while GHK-Cu contains a bound copper atom. The two differ in colour, charge, and binding behaviour, so any study that measures copper delivery must state which form was used.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.